CleftGeneDB-Search

Gene: EDNRB

Basic information

Tag	Content
Uniprot ID	P24530; A2A2Z8; A8K3T4; O15343; Q59GB1; Q5W0G9; Q8NHM6; Q8NHM7; Q8NHM8; Q8NHM9; Q9UD23; Q9UQK3;
Entrez ID	1910
Genbank protein ID	AAH14472.1; CAD30648.1; AAD24541.1; AAB25531.1; BAA14398.1; BAD92435.1; CAD30646.1; BAA02445.1; AAA58465.1; AAS38516.1; CAD30645.1; CAA67623.1; AAA52342.1; AAB19411.1; EAW80575.1; CAD30647.1; BAF83388.1; AAP32295.1; EAW80573.1;
Genbank nucleotide ID	NM_003991.3; NM_001201397.1; NM_001122659.2; NM_000115.4;
Ensembl protein ID	ENSP00000493527; ENSP00000487082; ENSP00000494278; ENSP00000493895; ENSP00000366416; ENSP00000486202;
Ensembl nucleotide ID	ENSG00000136160
Gene name	Endothelin receptor type B
Gene symbol	EDNRB
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Sequence	MQPPPSLCGR ALVALVLACG LSRIWGEERG FPPDRATPLL QTAEIMTPPT KTLWPKGSNA 60 SLARSLAPAE VPKGDRTAGS PPRTISPPPC QGPIEIKETF KYINTVVSCL VFVLGIIGNS 120 TLLRIIYKNK CMRNGPNILI ASLALGDLLH IVIDIPINVY KLLAEDWPFG AEMCKLVPFI 180 QKASVGITVL SLCALSIDRY RAVASWSRIK GIGVPKWTAV EIVLIWVVSV VLAVPEAIGF 240 DIITMDYKGS YLRICLLHPV QKTAFMQFYK TAKDWWLFSF YFCLPLAITA FFYTLMTCEM 300 LRKKSGMQIA LNDHLKQRRE VAKTVFCLVL VFALCWLPLH LSRILKLTLY NQNDPNRCEL 360 LSFLLVLDYI GINMASLNSC INPIALYLVS KRFKNCFKSC LCCWCQSFEE KQSLEEKQSC 420 LKFKANDHGY DNFRSSNKYS SS 442

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
5GLH
5GLI
5X93
5XPR
6IGK
6IGL
5GLI
5X93

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Species	Evidence	Details
1:1 ortholog	EDNRB	281750	P28088		Bos taurus	Prediction	More>>
1:1 ortholog	EDNRB	403862	F1PB15		Canis lupus familiaris	Prediction	More>>
1:1 ortholog	EDNRB	102186699	A0A452E880		Capra hircus	Prediction	More>>
1:1 ortholog	EDNRB	1910	P24530		Homo sapiens	Prediction	More>>
1:1 ortholog	Ednrb	13618	P48302	CPO,CLP	Mus musculus	Publication	More>>
1:1 ortholog	EDNRB	452613	H2Q7N9		Pan troglodytes	Prediction	More>>
1:1 ortholog	EDNRB	414911	P35463		Sus scrofa	Prediction	More>>
1:1 ortholog	EDNRB	100009477	D6CI21		Oryctolagus cuniculus	Prediction	More>>
1:1 ortholog	Ednrb	50672	P21451		Rattus norvegicus	Prediction	More>>
1:1 ortholog	ednrba	30442	Q9DGM2		Danio rerio	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1468720481	p.Gln2Arg	missense variant	-	NC_000013.11:g.77918569T>C	gnomAD
rs1406054889	p.Gln2His	missense variant	-	NC_000013.11:g.77918568C>A	gnomAD
rs200047993	p.Pro3Leu	missense variant	-	NC_000013.11:g.77918566G>A	ExAC,TOPMed,gnomAD
rs777992864	p.Pro4Ala	missense variant	-	NC_000013.11:g.77918564G>C	ExAC,gnomAD
rs12720160	p.Pro5Thr	missense variant	-	NC_000013.11:g.77918561G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs5345	p.Leu7Gln	missense variant	-	NC_000013.11:g.77918554A>T	-
rs5345	p.Leu7Gln	missense variant	-	NC_000013.11:g.77918554A>T	UniProt,dbSNP
VAR_014675	p.Leu7Gln	missense variant	-	NC_000013.11:g.77918554A>T	UniProt
rs1239813325	p.Leu7Met	missense variant	-	NC_000013.11:g.77918555G>T	gnomAD
rs765870134	p.Cys8Gly	missense variant	-	NC_000013.11:g.77918552A>C	ExAC,TOPMed,gnomAD
rs1204381719	p.Arg10Cys	missense variant	-	NC_000013.11:g.77918546G>A	gnomAD
rs754162462	p.Ala11Val	missense variant	-	NC_000013.11:g.77918542G>A	ExAC,gnomAD
rs548023225	p.Ala14Gly	missense variant	-	NC_000013.11:g.77918533G>C	1000Genomes,TOPMed
rs548023225	p.Ala14Val	missense variant	-	NC_000013.11:g.77918533G>A	1000Genomes,TOPMed
rs142767792	p.Val16Phe	missense variant	-	NC_000013.11:g.77918528C>A	1000Genomes,ExAC,TOPMed,gnomAD
rs142767792	p.Val16Leu	missense variant	-	NC_000013.11:g.77918528C>G	1000Genomes,ExAC,TOPMed,gnomAD
rs5346	p.Leu17Phe	missense variant	-	NC_000013.11:g.77918525G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs5346	p.Leu17Phe	missense variant	-	NC_000013.11:g.77918525G>A	UniProt,dbSNP
VAR_014676	p.Leu17Phe	missense variant	-	NC_000013.11:g.77918525G>A	UniProt
RCV000404231	p.Leu17Phe	missense variant	Waardenburg syndrome	NC_000013.11:g.77918525G>A	ClinVar
RCV000297140	p.Leu17Phe	missense variant	Hirschsprung Disease, Recessive	NC_000013.11:g.77918525G>A	ClinVar
VAR_078312	p.Leu17Pro	Missense	-	-	UniProt
rs762469442	p.Gly20Ser	missense variant	-	NC_000013.11:g.77918516C>T	ExAC,gnomAD
rs1382140942	p.Ser22Ala	missense variant	-	NC_000013.11:g.77918510A>C	gnomAD
rs769618877	p.Arg23Trp	missense variant	-	NC_000013.11:g.77918507G>A	ExAC,gnomAD
rs1235599209	p.Gly26Arg	missense variant	-	NC_000013.11:g.77918498C>T	gnomAD
rs551739242	p.Gly30Asp	missense variant	-	NC_000013.11:g.77918485C>T	1000Genomes,ExAC,gnomAD
rs200723251	p.Pro32Ser	missense variant	-	NC_000013.11:g.77918480G>A	ExAC,TOPMed,gnomAD
rs149740482	p.Asp34Glu	missense variant	-	NC_000013.11:g.77918472G>C	ESP,ExAC,TOPMed,gnomAD
rs1259767883	p.Arg35Thr	missense variant	-	NC_000013.11:g.77918470C>G	gnomAD
rs1354646550	p.Ala36Ser	missense variant	-	NC_000013.11:g.77918468C>A	gnomAD
rs752856831	p.Ala36Asp	missense variant	-	NC_000013.11:g.77918467G>T	ExAC
rs1288505904	p.Thr37Ile	missense variant	-	NC_000013.11:g.77918464G>A	gnomAD
rs779495524	p.Pro38Leu	missense variant	-	NC_000013.11:g.77918461G>A	ExAC,gnomAD
rs200304077	p.Ala43Ser	missense variant	-	NC_000013.11:g.77918447C>A	gnomAD
rs755457512	p.Glu44Val	missense variant	-	NC_000013.11:g.77918443T>A	ExAC
rs1401360436	p.Glu44Asp	missense variant	-	NC_000013.11:g.77918442C>A	TOPMed
rs990292887	p.Ile45Thr	missense variant	-	NC_000013.11:g.77918440A>G	TOPMed
rs1316261633	p.Thr47Lys	missense variant	-	NC_000013.11:g.77918434G>T	gnomAD
rs538237989	p.Pro48Leu	missense variant	-	NC_000013.11:g.77918431G>A	1000Genomes,TOPMed
rs139997339	p.Thr52Ile	missense variant	-	NC_000013.11:g.77918419G>A	ESP,TOPMed
rs766651046	p.Leu53Ser	missense variant	-	NC_000013.11:g.77918416A>G	ExAC,TOPMed,gnomAD
rs1362059171	p.Trp54Arg	missense variant	-	NC_000013.11:g.77918414A>G	gnomAD
rs751161032	p.Pro55Arg	missense variant	-	NC_000013.11:g.77918410G>C	ExAC,gnomAD
rs763764641	p.Lys56Thr	missense variant	-	NC_000013.11:g.77918407T>G	ExAC,TOPMed,gnomAD
rs1801710	p.Gly57Ser	missense variant	-	NC_000013.11:g.77918405C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
RCV000018117	p.Gly57Ser	missense variant	Hirschsprung disease 2 (HSCR2)	NC_000013.11:g.77918405C>T	ClinVar
rs142569954	p.Ala60Thr	missense variant	-	NC_000013.11:g.77918396C>T	ESP,ExAC,TOPMed,gnomAD
rs142569954	p.Ala60Pro	missense variant	-	NC_000013.11:g.77918396C>G	ESP,ExAC,TOPMed,gnomAD
rs201002254	p.Arg64Pro	missense variant	-	NC_000013.11:g.77918383C>G	ExAC,TOPMed,gnomAD
rs139147111	p.Arg64Trp	missense variant	-	NC_000013.11:g.77918384G>A	ESP,ExAC,TOPMed,gnomAD
rs139147111	p.Arg64Gly	missense variant	-	NC_000013.11:g.77918384G>C	ESP,ExAC,TOPMed,gnomAD
rs201002254	p.Arg64Leu	missense variant	-	NC_000013.11:g.77918383C>A	ExAC,TOPMed,gnomAD
rs201737510	p.Pro68Leu	missense variant	-	NC_000013.11:g.77918371G>A	TOPMed
RCV000606747	p.Pro68Leu	missense variant	-	NC_000013.11:g.77918371G>A	ClinVar
rs1019947807	p.Ala69Val	missense variant	-	NC_000013.11:g.77918368G>A	TOPMed
rs748181676	p.Glu70Lys	missense variant	-	NC_000013.11:g.77918366C>T	ExAC,gnomAD
RCV000627620	p.Val71Ter	frameshift	-	NC_000013.11:g.77918355_77918367del	ClinVar
rs150750272	p.Pro72Ser	missense variant	-	NC_000013.11:g.77918360G>A	ESP,ExAC,TOPMed,gnomAD
rs201488838	p.Lys73Glu	missense variant	-	NC_000013.11:g.77918357T>C	1000Genomes
rs1230438816	p.Asp75Asn	missense variant	-	NC_000013.11:g.77918351C>T	gnomAD
rs201207916	p.Arg76Gly	missense variant	-	NC_000013.11:g.77918348T>C	ExAC,TOPMed,gnomAD
rs201207916	p.Arg76Trp	missense variant	-	NC_000013.11:g.77918348T>A	ExAC,TOPMed,gnomAD
rs2228271	p.Arg76Met	missense variant	-	NC_000013.11:g.77918347C>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1227502849	p.Thr77Met	missense variant	-	NC_000013.11:g.77918344G>A	TOPMed,gnomAD
rs1227502849	p.Thr77Arg	missense variant	-	NC_000013.11:g.77918344G>C	TOPMed,gnomAD
rs1280900661	p.Gly79Ala	missense variant	-	NC_000013.11:g.77918338C>G	TOPMed,gnomAD
rs1280900661	p.Gly79Glu	missense variant	-	NC_000013.11:g.77918338C>T	TOPMed,gnomAD
rs1403988440	p.Ser80Phe	missense variant	-	NC_000013.11:g.77918335G>A	gnomAD
rs756427784	p.Pro81Leu	missense variant	-	NC_000013.11:g.77918332G>A	ExAC,TOPMed,gnomAD
rs771230818	p.Arg83Cys	missense variant	-	NC_000013.11:g.77918327G>A	ExAC,TOPMed,gnomAD
rs752412963	p.Thr84Ile	missense variant	-	NC_000013.11:g.77918323G>A	ExAC,gnomAD
rs752412963	p.Thr84Asn	missense variant	-	NC_000013.11:g.77918323G>T	ExAC,gnomAD
rs759133540	p.Pro87Ser	missense variant	-	NC_000013.11:g.77918315G>A	ExAC,gnomAD
rs1425908419	p.Pro87His	missense variant	-	NC_000013.11:g.77918314G>T	gnomAD
rs200756568	p.Pro88Leu	missense variant	-	NC_000013.11:g.77918311G>A	ExAC,TOPMed,gnomAD
rs1410175049	p.Pro88Ala	missense variant	-	NC_000013.11:g.77918312G>C	TOPMed,gnomAD
rs1028136288	p.Pro89Arg	missense variant	-	NC_000013.11:g.77918308G>C	TOPMed,gnomAD
rs148189360	p.Gly92Glu	missense variant	-	NC_000013.11:g.77918299C>T	ESP,ExAC,TOPMed,gnomAD
rs1235006032	p.Ile94Ser	missense variant	-	NC_000013.11:g.77918293A>C	TOPMed
rs772055405	p.Ile94Val	missense variant	-	NC_000013.11:g.77918294T>C	ExAC,gnomAD
rs774676772	p.Glu95Val	missense variant	-	NC_000013.11:g.77918290T>A	ExAC,gnomAD
rs1282405488	p.Glu95Gln	missense variant	-	NC_000013.11:g.77918291C>G	TOPMed
rs1280780830	p.Lys97Glu	missense variant	-	NC_000013.11:g.77918285T>C	gnomAD
rs768598369	p.Thr99Pro	missense variant	-	NC_000013.11:g.77918279T>G	ExAC,gnomAD
rs1064797178	p.Tyr102Ter	stop gained	-	NC_000013.11:g.77918268G>T	gnomAD
RCV000657773	p.Tyr102Ter	nonsense	-	NC_000013.11:g.77918268G>T	ClinVar
rs894919134	p.Ile103Val	missense variant	-	NC_000013.11:g.77918267T>C	TOPMed
rs780355308	p.Asn104Ile	missense variant	-	NC_000013.11:g.77918263T>A	ExAC,gnomAD
rs780355308	p.Asn104Ser	missense variant	-	NC_000013.11:g.77918263T>C	ExAC,gnomAD
rs368400131	p.Thr105Met	missense variant	-	NC_000013.11:g.77918260G>A	ESP,ExAC,TOPMed,gnomAD
RCV000778401	p.Cys109Ter	frameshift	EDNRB-Related Disorders	NC_000013.11:g.77918248del	ClinVar
rs1180581930	p.Leu110Val	missense variant	-	NC_000013.11:g.77918246G>C	TOPMed
rs1467139505	p.Val111Glu	missense variant	-	NC_000013.11:g.77918242A>T	gnomAD
rs5347	p.Phe112Val	missense variant	-	NC_000013.11:g.77918240A>C	UniProt,dbSNP
VAR_014677	p.Phe112Val	missense variant	-	NC_000013.11:g.77918240A>C	UniProt
rs5347	p.Phe112Val	missense variant	-	NC_000013.11:g.77918240A>C	-
rs781532939	p.Val113Met	missense variant	-	NC_000013.11:g.77918237C>T	ExAC,TOPMed,gnomAD
rs781532939	p.Val113Leu	missense variant	-	NC_000013.11:g.77918237C>G	ExAC,TOPMed,gnomAD
rs752268531	p.Leu114Pro	missense variant	-	NC_000013.11:g.77918233A>G	ExAC,gnomAD
RCV000521877	p.Gly115Glu	missense variant	-	NC_000013.11:g.77918230C>T	ClinVar
rs1555291991	p.Gly115Glu	missense variant	-	NC_000013.11:g.77918230C>T	-
rs559289370	p.Ile116Thr	missense variant	-	NC_000013.11:g.77918227A>G	1000Genomes
rs1439177895	p.Ile117Leu	missense variant	-	NC_000013.11:g.77918225T>G	TOPMed
rs541269180	p.Arg124Lys	missense variant	-	NC_000013.11:g.77918203C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs374619256	p.Asn129Lys	missense variant	-	NC_000013.11:g.77918187G>T	ESP,TOPMed
rs753395287	p.Lys130Thr	missense variant	-	NC_000013.11:g.77918185T>G	ExAC,TOPMed,gnomAD
rs1261885036	p.Cys131Arg	missense variant	-	NC_000013.11:g.77918183A>G	gnomAD
rs1396733251	p.Asn134Ile	missense variant	-	NC_000013.11:g.77918173T>A	TOPMed
rs760677132	p.Gly135Ser	missense variant	-	NC_000013.11:g.77918171C>T	ExAC,TOPMed,gnomAD
VAR_078313	p.Asn137Tyr	Missense	-	-	UniProt
rs1221743247	p.Ile138Val	missense variant	-	NC_000013.11:g.77918162T>C	gnomAD
rs371558629	p.Leu139Phe	missense variant	-	NC_000013.11:g.77918157C>G	ESP,ExAC,TOPMed,gnomAD
rs143042375	p.Leu139Val	missense variant	-	NC_000013.11:g.77918159A>C	ESP,ExAC,TOPMed,gnomAD
rs371558629	p.Leu139Phe	missense variant	-	NC_000013.11:g.77918157C>A	ESP,ExAC,TOPMed,gnomAD
rs1046390473	p.Ile140Met	missense variant	-	NC_000013.11:g.77918154G>C	TOPMed
rs762880632	p.Ala141Thr	missense variant	-	NC_000013.11:g.77918153C>T	ExAC,TOPMed,gnomAD
rs762880632	p.Ala141Ser	missense variant	-	NC_000013.11:g.77918153C>A	ExAC,TOPMed,gnomAD
rs1336072126	p.Gly146Ala	missense variant	-	NC_000013.11:g.77918137C>G	gnomAD
rs1399198786	p.His150Leu	missense variant	-	NC_000013.11:g.77918125T>A	gnomAD
rs769924328	p.Ile151Val	missense variant	-	NC_000013.11:g.77918123T>C	ExAC,gnomAD
rs1159624775	p.Ile153Thr	missense variant	-	NC_000013.11:g.77918116A>G	gnomAD
rs746343092	p.Asp154Gly	missense variant	-	NC_000013.11:g.77918113T>C	ExAC,gnomAD
VAR_078314	p.Pro156Arg	Missense	-	-	UniProt
rs368159798	p.Ile157Val	missense variant	-	NC_000013.11:g.77918105T>C	ESP,ExAC,TOPMed,gnomAD
rs1339942721	p.Gly170Arg	missense variant	-	NC_000013.11:g.77903583C>T	gnomAD
rs1402105082	p.Glu172Gln	missense variant	-	NC_000013.11:g.77903577C>G	gnomAD
rs772385532	p.Glu172Asp	missense variant	-	NC_000013.11:g.77903575C>G	ExAC,gnomAD
rs778187586	p.Glu172Ala	missense variant	-	NC_000013.11:g.77903576T>G	ExAC,gnomAD
RCV000659494	p.Cys174Ter	frameshift	Waardenburg syndrome type 4A (WS4A)	NC_000013.11:g.77903570del	ClinVar
rs143312578	p.Leu176Val	missense variant	-	NC_000013.11:g.77903565G>C	ESP,ExAC,TOPMed,gnomAD
rs1168969805	p.Val177Leu	missense variant	-	NC_000013.11:g.77903562C>A	gnomAD
rs201311945	p.Pro178Thr	missense variant	-	NC_000013.11:g.77903559G>T	ExAC,gnomAD
rs759131722	p.Ile180Met	missense variant	-	NC_000013.11:g.77903551T>C	ExAC,TOPMed,gnomAD
rs1423762419	p.Ile180Leu	missense variant	-	NC_000013.11:g.77903553T>G	gnomAD
rs1479241351	p.Gln181Glu	missense variant	-	NC_000013.11:g.77903550G>C	gnomAD
rs104894388	p.Ala183Gly	missense variant	-	NC_000013.11:g.77903543G>C	-
rs104894388	p.Ala183Gly	missense variant	Waardenburg syndrome 4A (WS4A)	NC_000013.11:g.77903543G>C	UniProt,dbSNP
VAR_003470	p.Ala183Gly	missense variant	Waardenburg syndrome 4A (WS4A)	NC_000013.11:g.77903543G>C	UniProt
RCV000018114	p.Ala183Gly	missense variant	Waardenburg syndrome type 4A (WS4A)	NC_000013.11:g.77903543G>C	ClinVar
rs1555290659	p.Ser184Pro	missense variant	-	NC_000013.11:g.77903541A>G	-
RCV000659495	p.Ser184Pro	missense variant	Waardenburg syndrome type 4A (WS4A)	NC_000013.11:g.77903541A>G	ClinVar
rs781214034	p.Val185Met	missense variant	-	NC_000013.11:g.77903538C>T	ExAC,TOPMed,gnomAD
RCV000758016	p.Val185Met	missense variant	Total intestinal aganglionosis	NC_000013.11:g.77903538C>T	ClinVar
rs1013425803	p.Ser191Cys	missense variant	-	NC_000013.11:g.77903520T>A	TOPMed,gnomAD
rs751513574	p.Ala194Val	missense variant	-	NC_000013.11:g.77903510G>A	ExAC,TOPMed,gnomAD
rs1258768009	p.Arg199Gly	missense variant	-	NC_000013.11:g.77903496T>C	gnomAD
rs780841273	p.Arg201Pro	missense variant	-	NC_000013.11:g.77903355C>G	ExAC,TOPMed,gnomAD
rs780841273	p.Arg201Gln	missense variant	-	NC_000013.11:g.77903355C>T	ExAC,TOPMed,gnomAD
RCV000659496	p.Arg201Ter	nonsense	Waardenburg syndrome type 4A (WS4A)	NC_000013.11:g.77903356G>A	ClinVar
rs104894391	p.Arg201Ter	stop gained	Abcd syndrome (abcds)	NC_000013.11:g.77903356G>A	ESP,ExAC,TOPMed,gnomAD
RCV000018120	p.Arg201Ter	nonsense	ABCD syndrome (ABCDS)	NC_000013.11:g.77903356G>A	ClinVar
rs1354645639	p.Ala202Val	missense variant	-	NC_000013.11:g.77903352G>A	TOPMed
rs202068468	p.Val203Phe	missense variant	-	NC_000013.11:g.77903350C>A	ExAC,gnomAD
rs202068468	p.Val203Ile	missense variant	-	NC_000013.11:g.77903350C>T	ExAC,gnomAD
rs202068468	p.Val203Leu	missense variant	-	NC_000013.11:g.77903350C>G	ExAC,gnomAD
rs876657688	p.Trp206Ter	stop gained	-	NC_000013.11:g.77903339C>T	gnomAD
RCV000221133	p.Trp206Ter	nonsense	Rare genetic deafness	NC_000013.11:g.77903339C>T	ClinVar
rs1410186437	p.Trp206Arg	missense variant	-	NC_000013.11:g.77903341A>G	TOPMed
rs746941725	p.Ser207Asn	missense variant	-	NC_000013.11:g.77903337C>T	ExAC,gnomAD
rs1361744218	p.Arg208Lys	missense variant	-	NC_000013.11:g.77903334C>T	gnomAD
rs932422479	p.Gly211Arg	missense variant	-	NC_000013.11:g.77903326C>T	TOPMed
rs752251497	p.Gly211Val	missense variant	-	NC_000013.11:g.77903325C>A	ExAC,TOPMed,gnomAD
rs1382035452	p.Ile212Thr	missense variant	-	NC_000013.11:g.77903322A>G	TOPMed,gnomAD
rs1440733865	p.Val214Ile	missense variant	-	NC_000013.11:g.77903317C>T	gnomAD
rs1255586825	p.Trp217Leu	missense variant	-	NC_000013.11:g.77903307C>A	TOPMed,gnomAD
rs1201160161	p.Thr218Ile	missense variant	-	NC_000013.11:g.77903304G>A	gnomAD
rs754126689	p.Leu224Ser	missense variant	-	NC_000013.11:g.77903286A>G	ExAC,TOPMed,gnomAD
rs766452784	p.Ile225Thr	missense variant	-	NC_000013.11:g.77903283A>G	ExAC,gnomAD
VAR_078315	p.Trp226_Ser442del	inframe_deletion	-	-	UniProt
rs1312043256	p.Val227Met	missense variant	-	NC_000013.11:g.77903278C>T	TOPMed,gnomAD
rs1334210764	p.Val228Ala	missense variant	-	NC_000013.11:g.77903274A>G	gnomAD
rs1340452566	p.Val228Phe	missense variant	-	NC_000013.11:g.77903275C>A	gnomAD
rs1397335747	p.Ala233Gly	missense variant	-	NC_000013.11:g.77903259G>C	gnomAD
rs1420013932	p.Ile238Thr	missense variant	-	NC_000013.11:g.77903244A>G	gnomAD
rs767943900	p.Ile238Val	missense variant	-	NC_000013.11:g.77903245T>C	ExAC,gnomAD
rs973740703	p.Gly239Arg	missense variant	-	NC_000013.11:g.77903242C>G	TOPMed,gnomAD
rs973740703	p.Gly239Ser	missense variant	-	NC_000013.11:g.77903242C>T	TOPMed,gnomAD
rs762204581	p.Asp241Asn	missense variant	-	NC_000013.11:g.77903236C>T	ExAC,gnomAD
rs201625400	p.Asp241Ala	missense variant	-	NC_000013.11:g.77903235T>G	ExAC,gnomAD
rs5350	p.Thr244Met	missense variant	-	NC_000013.11:g.77903226G>A	UniProt,dbSNP
VAR_014678	p.Thr244Met	missense variant	-	NC_000013.11:g.77903226G>A	UniProt
rs5350	p.Thr244Met	missense variant	-	NC_000013.11:g.77903226G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
RCV000325008	p.Thr244Met	missense variant	Waardenburg syndrome	NC_000013.11:g.77903226G>A	ClinVar
RCV000381908	p.Thr244Met	missense variant	Hirschsprung Disease, Recessive	NC_000013.11:g.77903226G>A	ClinVar
rs1216200131	p.Met245Lys	missense variant	-	NC_000013.11:g.77903223A>T	TOPMed,gnomAD
rs1216200131	p.Met245Thr	missense variant	-	NC_000013.11:g.77903223A>G	TOPMed,gnomAD
rs776468186	p.Met245Ile	missense variant	-	NC_000013.11:g.77903222C>T	ExAC,gnomAD
rs1288566827	p.Asp246Asn	missense variant	-	NC_000013.11:g.77903221C>T	gnomAD
rs371218105	p.Asp246Gly	missense variant	-	NC_000013.11:g.77903220T>C	ESP,ExAC,TOPMed,gnomAD
rs200272603	p.Tyr247Cys	missense variant	-	NC_000013.11:g.77903217T>C	ESP,ExAC,TOPMed,gnomAD
rs777697952	p.Lys248Thr	missense variant	-	NC_000013.11:g.77903214T>G	ExAC,gnomAD
rs758280131	p.Lys248Asn	missense variant	-	NC_000013.11:g.77903213T>A	ExAC,TOPMed,gnomAD
rs748143676	p.Gly249Arg	missense variant	-	NC_000013.11:g.77903212C>T	ExAC,gnomAD
rs199521140	p.Ser250Gly	missense variant	-	NC_000013.11:g.77903209T>C	ExAC,TOPMed,gnomAD
rs754807912	p.Ser250Ile	missense variant	-	NC_000013.11:g.77903208C>A	ExAC,gnomAD
rs754040927	p.Leu252Pro	missense variant	-	NC_000013.11:g.77903202A>G	ExAC,gnomAD
rs140514830	p.Arg253Gln	missense variant	-	NC_000013.11:g.77903199C>T	ESP,ExAC,TOPMed,gnomAD
rs104894390	p.Arg253Ter	stop gained	-	NC_000013.11:g.77903200G>A	ESP,ExAC,TOPMed,gnomAD
RCV000018119	p.Arg253Ter	nonsense	Waardenburg syndrome type 4A (WS4A)	NC_000013.11:g.77903200G>A	ClinVar
RCV000603036	p.Arg253Gln	missense variant	-	NC_000013.11:g.77903199C>T	ClinVar
rs371057149	p.Ile254Thr	missense variant	-	NC_000013.11:g.77903196A>G	ESP,ExAC,TOPMed,gnomAD
rs371057149	p.Ile254Asn	missense variant	-	NC_000013.11:g.77903196A>T	ESP,ExAC,TOPMed,gnomAD
rs750477425	p.Ile254Leu	missense variant	-	NC_000013.11:g.77903197T>G	ExAC,gnomAD
rs752147666	p.His258Gln	missense variant	-	NC_000013.11:g.77903183A>T	ExAC,gnomAD
rs368940609	p.His258Asp	missense variant	-	NC_000013.11:g.77903185G>C	ESP,ExAC,gnomAD
rs368940609	p.His258Tyr	missense variant	-	NC_000013.11:g.77903185G>A	ESP,ExAC,gnomAD
rs1265700652	p.Pro259Arg	missense variant	-	NC_000013.11:g.77903181G>C	gnomAD
rs200431358	p.Pro259Ser	missense variant	-	NC_000013.11:g.77903182G>A	ExAC,gnomAD
rs77132068	p.Val260Ile	missense variant	-	NC_000013.11:g.77903179C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs77132068	p.Val260Phe	missense variant	-	NC_000013.11:g.77903179C>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
RCV000839975	p.Val260Ile	missense variant	-	NC_000013.11:g.77903179C>T	ClinVar
rs1220991715	p.Val260Gly	missense variant	-	NC_000013.11:g.77903178A>C	TOPMed
RCV000614742	p.Val260Ile	missense variant	-	NC_000013.11:g.77903179C>T	ClinVar
rs1347740196	p.Thr263Ala	missense variant	-	NC_000013.11:g.77903170T>C	TOPMed
rs1212186974	p.Ala264Val	missense variant	-	NC_000013.11:g.77903166G>A	TOPMed,gnomAD
RCV000660537	p.Ala264Val	missense variant	Waardenburg syndrome type 4A (WS4A)	NC_000013.11:g.77903166G>A	ClinVar
rs1332382690	p.Phe268Leu	missense variant	-	NC_000013.11:g.77901207A>G	gnomAD
rs771549175	p.Lys270Gln	missense variant	-	NC_000013.11:g.77901201T>G	ExAC,gnomAD
rs1485754365	p.Thr271Ala	missense variant	-	NC_000013.11:g.77901198T>C	TOPMed
rs199937989	p.Asp274Asn	missense variant	-	NC_000013.11:g.77901189C>T	ExAC,gnomAD
rs142295388	p.Asp274Gly	missense variant	-	NC_000013.11:g.77901188T>C	ESP,ExAC,TOPMed,gnomAD
rs199937989	p.Asp274Tyr	missense variant	-	NC_000013.11:g.77901189C>A	ExAC,gnomAD
rs142295388	p.Asp274Val	missense variant	-	NC_000013.11:g.77901188T>A	ESP,ExAC,TOPMed,gnomAD
rs104894389	p.Trp275Ser	missense variant	-	NC_000013.11:g.77901185C>G	ExAC,gnomAD
rs1422704119	p.Trp275Gly	missense variant	-	NC_000013.11:g.77901186A>C	TOPMed
rs104894389	p.Trp275Ter	stop gained	-	NC_000013.11:g.77901185C>T	ExAC,gnomAD
RCV000018115	p.Trp275Ter	nonsense	Hirschsprung disease 2 (HSCR2)	NC_000013.11:g.77901185C>T	ClinVar
rs104894387	p.Trp276Cys	missense variant	Hirschsprung disease 2 (HSCR2)	NC_000013.11:g.77901181C>A	UniProt,dbSNP
VAR_003471	p.Trp276Cys	missense variant	Hirschsprung disease 2 (HSCR2)	NC_000013.11:g.77901181C>A	UniProt
rs104894387	p.Trp276Cys	missense variant	-	NC_000013.11:g.77901181C>A	ESP,TOPMed,gnomAD
RCV000018112	p.Trp276Cys	missense variant	Hirschsprung disease 2 (HSCR2)	NC_000013.11:g.77901181C>A	ClinVar
rs746051328	p.Ser279Asn	missense variant	-	NC_000013.11:g.77901173C>T	ExAC,gnomAD
rs746051328	p.Ser279Thr	missense variant	-	NC_000013.11:g.77901173C>G	ExAC,gnomAD
rs1280369607	p.Phe291Leu	missense variant	-	NC_000013.11:g.77901138A>G	gnomAD
VAR_015294	p.Phe292Leu	Missense	Waardenburg syndrome 4A (WS4A) [MIM:277580]	-	UniProt
rs1352720092	p.Tyr293His	missense variant	-	NC_000013.11:g.77901132A>G	gnomAD
rs1064797177	p.Tyr293Ter	stop gained	-	NC_000013.11:g.77901131dup	-
RCV000487897	p.Tyr293Ter	nonsense	-	NC_000013.11:g.77901131dup	ClinVar
RCV000018116	p.Tyr293Ter	frameshift	Hirschsprung disease 2 (HSCR2)	NC_000013.11:g.77901138dup	ClinVar
RCV000513371	p.Thr294Ter	frameshift	-	NC_000013.11:g.77901130dup	ClinVar
rs758958773	p.Thr294Ile	missense variant	-	NC_000013.11:g.77901128G>A	ExAC,gnomAD
rs765490586	p.Met296Leu	missense variant	-	NC_000013.11:g.77901123T>A	ExAC
rs112067501	p.Leu301Ser	missense variant	-	NC_000013.11:g.77901107A>G	gnomAD
rs112067501	p.Leu301Ter	stop gained	-	NC_000013.11:g.77901107A>T	gnomAD
rs1415699054	p.Arg302Lys	missense variant	-	NC_000013.11:g.77901104C>T	TOPMed
rs1336420198	p.Lys303Arg	missense variant	-	NC_000013.11:g.77901101T>C	gnomAD
rs376098154	p.Lys304Ile	missense variant	-	NC_000013.11:g.77901098T>A	ESP,ExAC,gnomAD
rs749996130	p.Lys304Asn	missense variant	-	NC_000013.11:g.77901097T>G	ExAC,TOPMed,gnomAD
rs5352	p.Ser305Asn	missense variant	-	NC_000013.11:g.77901095C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs5352	p.Ser305Asn	missense variant	-	NC_000013.11:g.77901095C>T	UniProt,dbSNP
VAR_003472	p.Ser305Asn	missense variant	-	NC_000013.11:g.77901095C>T	UniProt
RCV000018118	p.Ser305Asn	missense variant	Hirschsprung disease 2 (HSCR2)	NC_000013.11:g.77901095C>T	ClinVar
rs199558894	p.Gln308Lys	missense variant	-	NC_000013.11:g.77901087G>T	ExAC,gnomAD
rs944500117	p.Ala310Thr	missense variant	-	NC_000013.11:g.77901081C>T	TOPMed
rs907722017	p.Asp313Asn	missense variant	-	NC_000013.11:g.77901072C>T	TOPMed
rs907722017	p.Asp313Tyr	missense variant	-	NC_000013.11:g.77901072C>A	TOPMed
rs1238777762	p.Lys316Arg	missense variant	-	NC_000013.11:g.77901062T>C	gnomAD
rs759543922	p.Arg319Gln	missense variant	-	NC_000013.11:g.77900650C>T	ExAC,gnomAD
rs759543922	p.Arg319Leu	missense variant	-	NC_000013.11:g.77900650C>A	ExAC,gnomAD
rs200363611	p.Arg319Trp	missense variant	-	NC_000013.11:g.77900651G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs1233747891	p.Ala322Val	missense variant	-	NC_000013.11:g.77900641G>A	gnomAD
rs201437745	p.Val325Ile	missense variant	-	NC_000013.11:g.77900633C>T	ExAC,TOPMed,gnomAD
RCV000659498	p.Val325Ile	missense variant	Waardenburg syndrome type 4A (WS4A)	NC_000013.11:g.77900633C>T	ClinVar
rs1216944717	p.Leu328Met	missense variant	-	NC_000013.11:g.77900624G>T	gnomAD
rs1340103087	p.Val331Leu	missense variant	-	NC_000013.11:g.77900615C>G	gnomAD
rs1279092107	p.Ala333Val	missense variant	-	NC_000013.11:g.77900608G>A	gnomAD
RCV000758015	p.Pro338Leu	missense variant	Total intestinal aganglionosis	NC_000013.11:g.77900593G>A	ClinVar
rs1162021124	p.Lys346Arg	missense variant	-	NC_000013.11:g.77900569T>C	TOPMed
rs776554067	p.Thr348Ser	missense variant	-	NC_000013.11:g.77900564T>A	ExAC,gnomAD
rs1293406077	p.Leu349Phe	missense variant	-	NC_000013.11:g.77900561G>A	gnomAD
rs1437781516	p.Asn351Lys	missense variant	-	NC_000013.11:g.77900553A>T	gnomAD
rs1335692950	p.Asn351Asp	missense variant	-	NC_000013.11:g.77900555T>C	gnomAD
rs1397373759	p.Gln352Arg	missense variant	-	NC_000013.11:g.77900551T>C	TOPMed,gnomAD
rs1167913825	p.Asn353Lys	missense variant	-	NC_000013.11:g.77900547A>C	gnomAD
rs1295402804	p.Leu360His	missense variant	-	NC_000013.11:g.77900527A>T	gnomAD
rs369090616	p.Ser362Arg	missense variant	-	NC_000013.11:g.77900522T>G	TOPMed,gnomAD
rs180686892	p.Leu364Val	missense variant	-	NC_000013.11:g.77899963G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs180686892	p.Leu364Met	missense variant	-	NC_000013.11:g.77899963G>T	1000Genomes,ExAC,TOPMed,gnomAD
rs202171748	p.Tyr369Phe	missense variant	-	NC_000013.11:g.77899947T>A	TOPMed
rs1455429720	p.Ile370Thr	missense variant	-	NC_000013.11:g.77899944A>G	gnomAD
rs202153354	p.Gly371Cys	missense variant	-	NC_000013.11:g.77899942C>A	ExAC,TOPMed,gnomAD
rs202153354	p.Gly371Ser	missense variant	-	NC_000013.11:g.77899942C>T	ExAC,TOPMed,gnomAD
VAR_003474	p.Met374Ile	Missense	Hirschsprung disease 2 (HSCR2) [MIM:600155]	-	UniProt
rs1177969210	p.Leu377Val	missense variant	-	NC_000013.11:g.77899924G>C	gnomAD
rs200939685	p.Cys380Ser	missense variant	-	NC_000013.11:g.77899914C>G	ExAC,TOPMed,gnomAD
RCV000260247	p.Cys380Ser	missense variant	Hirschsprung Disease, Recessive	NC_000013.11:g.77899914C>G	ClinVar
RCV000299186	p.Cys380Ser	missense variant	Waardenburg syndrome	NC_000013.11:g.77899914C>G	ClinVar
rs1197671529	p.Ile381Val	missense variant	-	NC_000013.11:g.77899912T>C	gnomAD
VAR_003475	p.Pro383Leu	Missense	Hirschsprung disease 2 (HSCR2) [MIM:600155]	-	UniProt
rs567578805	p.Ile384Val	missense variant	-	NC_000013.11:g.77899903T>C	1000Genomes,ExAC,TOPMed,gnomAD
rs1466632176	p.Lys391Gln	missense variant	-	NC_000013.11:g.77899882T>G	TOPMed
rs773530703	p.Lys391Arg	missense variant	-	NC_000013.11:g.77899881T>C	ExAC,TOPMed,gnomAD
rs772345263	p.Phe393Leu	missense variant	-	NC_000013.11:g.77899874G>C	ExAC,gnomAD
rs1396007412	p.Phe397Tyr	missense variant	-	NC_000013.11:g.77899863A>T	TOPMed
rs1378362046	p.Phe397Val	missense variant	-	NC_000013.11:g.77899864A>C	TOPMed,gnomAD
rs750260325	p.Ser399Pro	missense variant	-	NC_000013.11:g.77898334A>G	ExAC,TOPMed,gnomAD
rs750260325	p.Ser399Thr	missense variant	-	NC_000013.11:g.77898334A>T	ExAC,TOPMed,gnomAD
rs1312925422	p.Cys400Trp	missense variant	-	NC_000013.11:g.77898329G>C	TOPMed,gnomAD
rs1364508724	p.Leu401Phe	missense variant	-	NC_000013.11:g.77898326T>G	TOPMed
rs767275433	p.Trp404Ter	stop gained	-	NC_000013.11:g.77898318C>T	ExAC,TOPMed,gnomAD
rs1297352198	p.Phe408Leu	missense variant	-	NC_000013.11:g.77898307A>G	gnomAD
rs1319801057	p.Ser413Phe	missense variant	-	NC_000013.11:g.77898291G>A	TOPMed
rs762094666	p.Ser413Thr	missense variant	-	NC_000013.11:g.77898292A>T	ExAC,gnomAD
rs200548885	p.Ser419Leu	missense variant	-	NC_000013.11:g.77898273G>A	ESP,ExAC,TOPMed,gnomAD
rs200720978	p.Lys422Glu	missense variant	-	NC_000013.11:g.77898265T>C	ExAC,gnomAD
rs1375298638	p.Lys422Asn	missense variant	-	NC_000013.11:g.77898263C>G	gnomAD
rs1359074336	p.Lys424Glu	missense variant	-	NC_000013.11:g.77898259T>C	TOPMed
rs771239282	p.Ala425Pro	missense variant	-	NC_000013.11:g.77898256C>G	ExAC,gnomAD
rs747813758	p.Asn426Lys	missense variant	-	NC_000013.11:g.77898251A>C	ExAC,TOPMed,gnomAD
rs1217607090	p.Asn426Asp	missense variant	-	NC_000013.11:g.77898253T>C	TOPMed
rs778453066	p.Asp427Gly	missense variant	-	NC_000013.11:g.77898249T>C	ExAC,gnomAD
rs754498240	p.His428Gln	missense variant	-	NC_000013.11:g.77898245G>T	ExAC,TOPMed,gnomAD
rs1238508690	p.His428Arg	missense variant	-	NC_000013.11:g.77898246T>C	TOPMed
rs1215746671	p.His428Tyr	missense variant	-	NC_000013.11:g.77898247G>A	TOPMed
rs1315670514	p.Gly429Glu	missense variant	-	NC_000013.11:g.77898243C>T	gnomAD
RCV000402655	p.Gly429Arg	missense variant	Waardenburg syndrome	NC_000013.11:g.77898244C>T	ClinVar
RCV000310434	p.Gly429Arg	missense variant	Hirschsprung Disease, Recessive	NC_000013.11:g.77898244C>T	ClinVar
RCV000220584	p.Gly429Arg	missense variant	-	NC_000013.11:g.77898244C>T	ClinVar
rs144565124	p.Gly429Arg	missense variant	-	NC_000013.11:g.77898244C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs568662694	p.Tyr430His	missense variant	-	NC_000013.11:g.77898241A>G	1000Genomes,ExAC,gnomAD
rs750396591	p.Arg434Ser	missense variant	-	NC_000013.11:g.77898229G>T	ExAC,TOPMed,gnomAD
rs750396591	p.Arg434Cys	missense variant	-	NC_000013.11:g.77898229G>A	ExAC,TOPMed,gnomAD
rs201243241	p.Arg434His	missense variant	-	NC_000013.11:g.77898228C>T	ExAC,TOPMed,gnomAD
rs757021438	p.Ser435Tyr	missense variant	-	NC_000013.11:g.77898225G>T	ExAC,TOPMed,gnomAD
rs757021438	p.Ser435Phe	missense variant	-	NC_000013.11:g.77898225G>A	ExAC,TOPMed,gnomAD
rs751760790	p.Ser436Gly	missense variant	-	NC_000013.11:g.77898223T>C	ExAC,gnomAD
rs764302607	p.Ser436Thr	missense variant	-	NC_000013.11:g.77898222C>G	ExAC,gnomAD
rs762959381	p.Ser441Leu	missense variant	-	NC_000013.11:g.77898207G>A	ExAC,gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0000737	Abdominal Pain	phenotype	HPO
C0001418	Adenocarcinoma	group	BEFREE
C0001430	Adenoma	group	BEFREE
C0001486	Adenovirus Infections	group	BEFREE
C0001883	Airway Obstruction	group	LHGDN
C0001916	Albinism	disease	HPO
C0001973	Alcoholic Intoxication, Chronic	disease	BEFREE
C0003130	Anoxia	phenotype	LHGDN
C0003873	Rheumatoid Arthritis	disease	BEFREE
C0004096	Asthma	disease	BEFREE;LHGDN;RGD
C0004114	Astrocytoma	disease	BEFREE
C0004153	Atherosclerosis	disease	LHGDN
C0004238	Atrial Fibrillation	disease	BEFREE
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE
C0005695	Bladder Neoplasm	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE;CTD_human
C0007103	Malignant neoplasm of endometrium	disease	BEFREE
C0007112	Adenocarcinoma of prostate	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE;LHGDN
C0007137	Squamous cell carcinoma	disease	BEFREE;LHGDN
C0007193	Cardiomyopathy, Dilated	group	BEFREE;LHGDN
C0007222	Cardiovascular Diseases	group	BEFREE
C0007758	Cerebellar Ataxia	phenotype	HPO
C0007785	Cerebral Infarction	disease	BEFREE
C0008497	Choriocarcinoma	disease	BEFREE
C0009402	Colorectal Carcinoma	disease	BEFREE
C0009806	Constipation	phenotype	BEFREE;HPO
C0010054	Coronary Arteriosclerosis	disease	BEFREE
C0010674	Cystic Fibrosis	disease	BEFREE
C0011053	Deafness	phenotype	HPO
C0011644	Scleroderma	disease	BEFREE
C0011860	Diabetes Mellitus, Non-Insulin-Dependent	disease	BEFREE;CTD_human;RGD
C0013080	Down Syndrome	disease	LHGDN
C0013274	Patent ductus arteriosus	disease	BEFREE
C0014356	Enterocolitis	disease	BEFREE
C0017601	Glaucoma	disease	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE;LHGDN
C0018772	Hearing Loss, Partial	phenotype	HPO
C0018776	Hearing Loss, Central	disease	RGD
C0018780	Hearing Loss, High-Frequency	disease	RGD
C0018784	Sensorineural Hearing Loss (disorder)	disease	HPO;RGD
C0018801	Heart failure	disease	BEFREE;CTD_human;LHGDN
C0018802	Congestive heart failure	disease	BEFREE;CTD_human
C0019196	Hepatitis C	disease	BEFREE
C0019284	Diaphragmatic Hernia	phenotype	CTD_human
C0019569	Hirschsprung Disease	disease	BEFREE;CTD_human;HPO;LHGDN;MGD;ORPHANET;RGD
C0020538	Hypertensive disease	group	BEFREE;LHGDN;RGD
C0020541	Hypertension, Portal	disease	RGD
C0020542	Pulmonary Hypertension	phenotype	CTD_human;RGD
C0021100	Bullous impetigo	disease	BEFREE
C0021843	Intestinal Obstruction	disease	BEFREE;HPO
C0022658	Kidney Diseases	group	BEFREE
C0023212	Left-Sided Heart Failure	disease	CTD_human
C0023264	Leigh Disease	disease	BEFREE
C0023267	Fibroid Tumor	group	BEFREE
C0023418	leukemia	disease	LHGDN
C0023520	Leukodystrophy	disease	HPO
C0023890	Liver Cirrhosis	disease	BEFREE
C0024115	Lung diseases	group	BEFREE
C0024117	Chronic Obstructive Airway Disease	disease	BEFREE
C0024121	Lung Neoplasms	group	BEFREE;LHGDN
C0024312	Lymphopenia	disease	RGD
C0025160	Megacolon	phenotype	HPO;RGD
C0025202	melanoma	disease	BEFREE;LHGDN
C0025286	Meningioma	disease	BEFREE
C0025958	Microcephaly	disease	BEFREE
C0026827	Muscle hypotonia	phenotype	HPO
C0027051	Myocardial Infarction	disease	BEFREE;RGD
C0027498	Nausea and vomiting	phenotype	HPO
C0027626	Neoplasm Invasiveness	phenotype	CTD_human
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0027720	Nephrosis	disease	CTD_human
C0027819	Neuroblastoma	group	BEFREE
C0028738	Nystagmus	disease	HPO
C0028754	Obesity	disease	BEFREE
C0028840	Ocular Hypertension	disease	BEFREE
C0028945	oligodendroglioma	disease	LHGDN
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029463	Osteosarcoma	disease	BEFREE
C0030193	Pain	phenotype	BEFREE
C0031117	Peripheral Neuropathy	group	HPO
C0031511	Pheochromocytoma	disease	BEFREE
C0032927	Precancerous Conditions	group	BEFREE
C0033578	Prostatic Neoplasms	group	BEFREE
C0036220	Kaposi Sarcoma	disease	BEFREE;LHGDN
C0036421	Systemic Scleroderma	disease	BEFREE
C0036651	Senile lentigo	disease	BEFREE
C0037278	Skin Diseases, Infectious	group	BEFREE
C0037286	Skin Neoplasms	group	BEFREE
C0037771	Paraparesis, Spastic	phenotype	HPO
C0038165	Staphylococcal Scalded Skin Syndrome	disease	BEFREE
C0038454	Cerebrovascular accident	group	BEFREE
C0038525	Subarachnoid Hemorrhage	disease	CTD_human
C0039483	Giant Cell Arteritis	disease	BEFREE
C0041296	Tuberculosis	disease	BEFREE
C0042133	Uterine Fibroids	group	BEFREE
C0085413	Polycystic Kidney, Autosomal Dominant	disease	LHGDN
C0085758	Aganglionosis, Colonic	disease	BEFREE;CTD_human
C0149925	Small cell carcinoma of lung	disease	BEFREE
C0149931	Migraine Disorders	group	BEFREE
C0151546	Oral Cavity Carcinoma	disease	BEFREE
C0151744	Myocardial Ischemia	disease	BEFREE;LHGDN
C0151891	Retinal depigmentation	phenotype	HPO
C0152025	Polyneuropathy	disease	HPO
C0152171	Idiopathic pulmonary hypertension	disease	BEFREE
C0153349	Malignant neoplasm of tongue	disease	BEFREE
C0153381	Malignant neoplasm of mouth	disease	BEFREE
C0153690	Secondary malignant neoplasm of bone	disease	BEFREE
C0154723	Migraine with Aura	disease	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0205748	Dysplastic Nevus	disease	BEFREE
C0206686	Adrenocortical carcinoma	disease	BEFREE
C0206698	Cholangiocarcinoma	disease	BEFREE
C0220633	Uveal melanoma	disease	BEFREE
C0220641	Lip and Oral Cavity Carcinoma	disease	BEFREE
C0232487	Abdominal discomfort	phenotype	HPO
C0235480	Paroxysmal atrial fibrillation	disease	BEFREE
C0235527	Heart Failure, Right-Sided	disease	CTD_human
C0235833	Congenital diaphragmatic hernia	disease	BEFREE
C0237326	Dyschezia	phenotype	HPO
C0238462	Medullary carcinoma of thyroid	disease	BEFREE
C0238463	Papillary thyroid carcinoma	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0242852	Proliferative vitreoretinopathy	disease	LHGDN
C0263009	Sclerosis of the skin	disease	BEFREE
C0263498	Premature canities	phenotype	HPO
C0264716	Chronic heart failure	disease	BEFREE
C0268731	Renal glomerular disease	group	BEFREE
C0270192	Perinatal Subarachnoid Hemorrhage	phenotype	CTD_human
C0278883	Metastatic melanoma	disease	BEFREE
C0278996	Malignant Head and Neck Neoplasm	disease	BEFREE
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0279702	Conventional (Clear Cell) Renal Cell Carcinoma	disease	BEFREE
C0312414	Menstrual spotting	phenotype	BEFREE
C0333913	Achromasia	phenotype	HPO
C0339543	Epiretinal Membrane	phenotype	BEFREE
C0339789	Congenital deafness	disease	BEFREE;HPO
C0340543	Familial primary pulmonary hypertension	disease	BEFREE
C0343401	MRSA - Methicillin resistant Staphylococcus aureus infection	disease	BEFREE
C0344312	White forelock	phenotype	HPO
C0345244	Neuronal intestinal dysplasia	disease	BEFREE
C0346629	Malignant neoplasm of large intestine	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0423318	Heterochromia iridis	phenotype	HPO
C0431447	Synophrys	disease	HPO
C0472383	Subarachnoid Hemorrhage, Spontaneous	phenotype	CTD_human
C0476089	Endometrial Carcinoma	disease	BEFREE
C0520679	Sleep Apnea, Obstructive	disease	BEFREE
C0521158	Recurrent tumor	phenotype	BEFREE
C0522216	Abnormal auditory evoked potential	phenotype	HPO
C0553580	Ewings sarcoma	disease	BEFREE
C0555198	Malignant Glioma	disease	BEFREE
C0557874	Global developmental delay	disease	HPO
C0563625	Agnosia for Pain	disease	BEFREE
C0578626	blue iris (physical finding)	phenotype	HPO
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596240	Cancer Pain	phenotype	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0600327	Toxic Shock Syndrome	disease	BEFREE
C0600452	Hepatopulmonary Syndrome	disease	RGD
C0678222	Breast Carcinoma	disease	BEFREE;CTD_human
C0684249	Carcinoma of lung	disease	BEFREE
C0687713	Gastrointestinal pain	phenotype	HPO
C0699885	Carcinoma of bladder	disease	BEFREE
C0700095	Central neuroblastoma	disease	BEFREE
C0751530	Subarachnoid Hemorrhage, Aneurysmal	phenotype	CTD_human
C0795688	Subarachnoid Hemorrhage, Intracranial	phenotype	CTD_human
C0856169	Endothelial dysfunction	phenotype	BEFREE
C0856554	Hepatic cancer metastatic	disease	BEFREE
C0878544	Cardiomyopathies	group	BEFREE
C0917798	Cerebral Ischemia	disease	BEFREE
C0948008	Ischemic stroke	disease	BEFREE
C1168327	High-Grade Prostatic Intraepithelial Neoplasia	disease	BEFREE
C1168401	Squamous cell carcinoma of the head and neck	disease	BEFREE
C1257840	Aganglionosis, Rectosigmoid Colon	disease	CTD_human
C1257931	Mammary Neoplasms, Human	group	CTD_human
C1258666	Myxoid cyst	disease	LHGDN
C1262477	Weight decreased	phenotype	HPO
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1384666	hearing impairment	phenotype	HPO
C1449563	Cardiomyopathy, Familial Idiopathic	disease	BEFREE
C1458155	Mammary Neoplasms	group	CTD_human;LHGDN
C1510420	Cavitation	phenotype	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1535510	ADENOMAS AND ADENOCARCINOMAS	group	BEFREE
C1623038	Cirrhosis	disease	BEFREE
C1658953	tumor vasculature	phenotype	BEFREE
C1704272	Benign Prostatic Hyperplasia	disease	BEFREE
C1834055	Underdeveloped nasal alae	phenotype	HPO
C1836729	Autonomic dysregulation	phenotype	HPO
C1836735	hypopigmented skin patch	phenotype	HPO
C1836736	White eyelashes	phenotype	HPO
C1836737	White eyebrow	phenotype	HPO
C1838099	ABCD syndrome	disease	BEFREE;CLINVAR;CTD_human
C1838564	HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 2	phenotype	CLINVAR;UNIPROT
C1839764	Broad flat nasal bridge	phenotype	HPO
C1848395	Large for gestational age	phenotype	HPO
C1848519	WAARDENBURG SYNDROME, TYPE 4A	disease	BEFREE;CLINVAR;CTD_human;MGD;ORPHANET;UNIPROT
C1849367	Nasal bridge wide	phenotype	HPO
C1854113	Prominent nasal bridge	phenotype	HPO
C1855331	Olfactory lobe agenesis	phenotype	HPO
C1864897	Cognitive delay	phenotype	HPO
C1883486	Uterine Corpus Cancer	disease	BEFREE
C1959583	Myocardial Failure	disease	CTD_human
C1961112	Heart Decompensation	phenotype	CTD_human
C2239176	Liver carcinoma	disease	BEFREE
C2700265	Waardenburg Syndrome Type 2	disease	BEFREE;ORPHANET
C2931822	Nasopharyngeal carcinoma	disease	BEFREE
C3203102	Idiopathic pulmonary arterial hypertension	disease	BEFREE
C3266898	Waardenburg Syndrome	disease	CLINVAR;ORPHANET
C3661523	Congenital Intestinal Aganglionosis	disease	BEFREE;CTD_human;ORPHANET
C3714602	Staphylococcal toxic shock syndrome	disease	BEFREE
C3714756	Intellectual Disability	group	GENOMICS_ENGLAND
C4020875	Mental and motor retardation	phenotype	HPO
C4025846	Abnormality of vision	phenotype	HPO
C4230640	Convex nasal bridge	phenotype	HPO
C4280578	Grey eyelashes	phenotype	HPO
C4280579	Grey eyebrow	phenotype	HPO
C4280580	Blonde eyebrow	phenotype	HPO
C4520679	Abnormal macular morphology	phenotype	HPO

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0004962	endothelin receptor activity	IDA
GO:0004962	endothelin receptor activity	IMP
GO:0005515	protein binding	IPI
GO:0017046	peptide hormone binding	IPI
GO:0031702	type 1 angiotensin receptor binding	IEA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000122	negative regulation of transcription by RNA polymerase II	ISS
GO:0000122	negative regulation of transcription by RNA polymerase II	IMP
GO:0001755	neural crest cell migration	IEA
GO:0001934	positive regulation of protein phosphorylation	IEA
GO:0006885	regulation of pH	IEA
GO:0007166	cell surface receptor signaling pathway	TAS
GO:0007186	G protein-coupled receptor signaling pathway	TAS
GO:0007194	negative regulation of adenylate cyclase activity	TAS
GO:0007200	phospholipase C-activating G protein-coupled receptor signaling pathway	IEA
GO:0007204	positive regulation of cytosolic calcium ion concentration	IEA
GO:0007399	nervous system development	TAS
GO:0007422	peripheral nervous system development	IEA
GO:0007497	posterior midgut development	IEA
GO:0007568	aging	IEA
GO:0008217	regulation of blood pressure	IEA
GO:0008284	positive regulation of cell population proliferation	IEA
GO:0014043	negative regulation of neuron maturation	ISS
GO:0014070	response to organic cyclic compound	IEA
GO:0014826	vein smooth muscle contraction	IMP
GO:0019233	sensory perception of pain	IEA
GO:0019722	calcium-mediated signaling	IMP
GO:0019934	cGMP-mediated signaling	IEA
GO:0030318	melanocyte differentiation	IEA
GO:0031620	regulation of fever generation	IEA
GO:0032269	negative regulation of cellular protein metabolic process	IMP
GO:0035645	enteric smooth muscle cell differentiation	ISS
GO:0035810	positive regulation of urine volume	IEA
GO:0035815	positive regulation of renal sodium excretion	IEA
GO:0042045	epithelial fluid transport	IEA
GO:0042310	vasoconstriction	IMP
GO:0042311	vasodilation	IEA
GO:0043066	negative regulation of apoptotic process	IEA
GO:0048246	macrophage chemotaxis	IMP
GO:0048265	response to pain	IEA
GO:0048484	enteric nervous system development	ISS
GO:0050678	regulation of epithelial cell proliferation	IEA
GO:0051930	regulation of sensory perception of pain	IEA
GO:0060406	positive regulation of penile erection	IEA
GO:0071222	cellular response to lipopolysaccharide	IEA
GO:0086100	endothelin receptor signaling pathway	IDA
GO:0086100	endothelin receptor signaling pathway	IMP
GO:1990839	response to endothelin	IEA

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005623	cell	IEA
GO:0005886	plasma membrane	IDA
GO:0005886	plasma membrane	TAS
GO:0005887	integral component of plasma membrane	TAS
GO:0031965	nuclear membrane	IEA
GO:0045121	membrane raft	IEA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-162582	Signal Transduction	TAS
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)	TAS
R-HSA-375276	Peptide ligand-binding receptors	TAS
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-416476	G alpha (q) signalling events	TAS
R-HSA-500792	GPCR ligand binding	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C026486	1,2,5,6-dibenzanthracene	1,2,5,6-dibenzanthracene results in decreased expression of EDNRB mRNA	26377693
C020888	1,2-dielaidoylphosphatidylethanolamine	1,2-dielaidoylphosphatidylethanolamine results in decreased expression of EDNRB mRNA alternative form	14668052
C049325	1,2-dithiol-3-thione	1,2-dithiol-3-thione results in decreased expression of EDNRB mRNA	19162173
C095653	1,5-dihydroxyisoquinoline	1,5-dihydroxyisoquinoline results in decreased expression of EDNRB mRNA	12824290
C060229	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C060229	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione	1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C040168	19-oxo-11-deoxycorticosterone acetate	[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA	18823320
C040168	19-oxo-11-deoxycorticosterone acetate	Atrasentan inhibits the reaction [[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA]	18823320
C087551	1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)-	1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)- binds to and results in decreased activity of EDNRB protein	14687651
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDNRB mRNA	28628672
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of EDNRB mRNA	28628672
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]	20561571
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]	20561571
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter promotes the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]]	20561571
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter promotes the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]]	20561571
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
C006551	2-amino-2-methyl-1-propanol	2-amino-2-methyl-1-propanol results in decreased expression of EDNRB mRNA	25088246
C109986	2-aminoethoxydiphenyl borate	2-aminoethoxydiphenyl borate inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C109986	2-aminoethoxydiphenyl borate	2-aminoethoxydiphenyl borate inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C434003	3-(4-methylphenylsulfonyl)-2-propenenitrile	3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Cyclosporine results in increased expression of EDNRB mRNA]	25772258
C434003	3-(4-methylphenylsulfonyl)-2-propenenitrile	3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Cyclosporine results in increased expression of EDNRB protein]	25772258
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of EDNRB mRNA	20382639
C080122	7-nitroindazole	7-nitroindazole inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C080122	7-nitroindazole	7-nitroindazole inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C016276	8-bromocyclic GMP	8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]	16023617
C016276	8-bromocyclic GMP	8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]	16023617
D015127	9,10-Dimethyl-1,2-benzanthracene	9,10-Dimethyl-1,2-benzanthracene results in decreased expression of EDNRB mRNA	19480007
C467893	A 182086	A 182086 binds to and results in decreased activity of EDNRB protein	12875994
C120508	A 192621	A 192621 binds to and results in decreased activity of EDNRB protein	19040731
C120508	A 192621	A 192621 binds to and results in decreased activity of EDNRB protein	10877991; 11994508; 14973117; 15371886;
C095427	A 86929	A 86929 binds to EDNRB protein	8558425
D000082	Acetaminophen	Acetaminophen results in decreased expression of EDNRB mRNA	29067470
D000082	Acetaminophen	Acetaminophen results in increased expression of EDNRB mRNA	21420995
D000082	Acetaminophen	Acetaminophen affects the expression of EDNRB mRNA	17562736
D020106	Acrylamide	Acrylamide results in decreased expression of EDNRB mRNA	28959563
D000496	Alloxan	Alloxan results in increased expression of EDNRB mRNA	12605241
D000496	Alloxan	Alloxan results in increased expression of EDNRB protein	12605241
C557933	AMG 837	AMG 837 results in increased expression of EDNRB mRNA	30243991
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of EDNRB mRNA	16483693
D000666	Amphotericin B	Amphotericin B results in increased expression of EDNRB mRNA	20849824
D000804	Angiotensin II	Angiotensin II results in increased expression of EDNRB protein	15007106
D001151	Arsenic	Arsenic results in decreased expression of EDNRB mRNA	19654921
D000077237	Arsenic Trioxide	Arsenic Trioxide results in decreased expression of EDNRB mRNA	26705709
D000077237	Arsenic Trioxide	Arsenic Trioxide results in increased expression of EDNRB mRNA alternative form	19128835
D017632	Asbestos, Serpentine	Asbestos, Serpentine results in increased methylation of EDNRB 5' UTR	29523930
D001205	Ascorbic Acid	Ascorbic Acid results in increased expression of EDNRB mRNA	15305145
D001241	Aspirin	Aspirin inhibits the reaction [IL1B results in increased activity of EDNRB]	12126971
D000077868	Atrasentan	Atrasentan inhibits the reaction [[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA]	18823320
C547126	AZM551248	AZM551248 results in decreased expression of EDNRB mRNA	22323515
C487081	belinostat	belinostat results in increased expression of EDNRB mRNA	26272509
C487081	belinostat	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C061004	benidipine	benidipine results in decreased expression of EDNRB protein	16387788
C030935	benz(a)anthracene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA	27858113
D001564	Benzo(a)pyrene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA	27858113
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of EDNRB mRNA	22228805; 22610609;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of EDNRB mRNA	19770486; 21964900;
C006703	benzo(b)fluoranthene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA	27858113
C006703	benzo(b)fluoranthene	benzo(b)fluoranthene results in decreased expression of EDNRB mRNA	26377693
D000077610	Bexarotene	Bexarotene results in increased expression of EDNRB mRNA	16648578
C070515	bisindolylmaleimide I	bisindolylmaleimide I inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C070515	bisindolylmaleimide I	bisindolylmaleimide I inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C006780	bisphenol A	bisphenol A results in increased methylation of EDNRB promoter	27271280
C006780	bisphenol A	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDNRB mRNA	28628672
C006780	bisphenol A	bisphenol A results in decreased expression of EDNRB mRNA	30816183
C006780	bisphenol A	bisphenol A results in increased expression of EDNRB mRNA	25181051
C000611646	bisphenol F	bisphenol F results in decreased expression of EDNRB mRNA	30951980
D000077300	Bosentan	Bosentan binds to and results in decreased activity of EDNRB protein	15334381
D000077300	Bosentan	Bosentan binds to and results in decreased activity of EDNRB protein	16219361
D000077300	Bosentan	Bosentan binds to and results in decreased activity of EDNRB protein	10796056; 11922906; 15093706; 16335785; 16700825; 16741059; 17234519; 20967148; 22483689; 7828305; 8572876; 8587695; 8604712; 8794820; 9052893;
C086539	BQ 788	BQ 788 binds to and results in decreased activity of EDNRB protein	19040731
C086539	BQ 788	BQ 788 binds to and results in decreased activity of EDNRB protein	16151434; 21259319;
C086539	BQ 788	BQ 788 inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C086539	BQ 788	BQ 788 inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C086539	BQ 788	BQ 788 results in decreased expression of EDNRB protein	24462674
C086539	BQ 788	Celecoxib inhibits the reaction [BQ 788 results in decreased expression of EDNRB protein]	24462674
C086539	BQ 788	Celecoxib results in decreased susceptibility to [BQ 788 binds to and results in decreased activity of EDNRB protein]	24462674
C086539	BQ 788	BQ 788 binds to and results in decreased activity of EDNRB protein	11028503; 12363203; 12686472; 14736733; 15093706; 15245872; 15334381; 15357834; 15464066; 15680467; 16023617; 16280098; 16391412; 17414428; 18660453; 19429182; 24462674;
C086539	BQ 788	BQ 788 results in decreased activity of EDNRB protein	15605384; 28700113;
D002117	Calcitriol	Calcitriol results in increased expression of EDNRB mRNA	12230499
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in decreased expression of EDNRB mRNA	17484886
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of EDNRB mRNA	29987408
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in decreased expression of EDNRB mRNA	16644059
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased activity of EDNRB protein	12873816
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of EDNRB mRNA	12873816; 16239168; 31150632;
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of EDNRB protein	12708965
D002251	Carbon Tetrachloride	EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]	18205269
D000068579	Celecoxib	Celecoxib inhibits the reaction [BQ 788 results in decreased expression of EDNRB protein]	24462674
D000068579	Celecoxib	Celecoxib inhibits the reaction [Cyclosporine results in decreased expression of EDNRB protein]	24462674
D000068579	Celecoxib	Celecoxib inhibits the reaction [Cyclosporine results in increased expression of EDNRB protein]	25656942
D000068579	Celecoxib	Celecoxib results in decreased susceptibility to [BQ 788 binds to and results in decreased activity of EDNRB protein]	24462674
D002699	Chlorambucil	Chlorambucil results in increased mutagenesis of EDNRB gene	10517996
D002737	Chloroprene	Chloroprene results in increased expression of EDNRB mRNA	23125180
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of EDNRB mRNA	20691718
D002793	Cholic Acids	[Ethinyl Estradiol co-treated with Cholic Acids] affects the expression of EDNRB mRNA	27344345
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of EDNRB mRNA	20938992
D002857	Chromium	LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of EDNRB mRNA]	16940432
C031180	chrysene	[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of EDNRB mRNA	27858113
C418118	CI 1044	CI 1044 results in increased expression of EDNRB mRNA	17569694
D002945	Cisplatin	Cisplatin results in increased expression of EDNRB mRNA	20849824
D003042	Cocaine	Cocaine affects the expression of EDNRB mRNA	20187946
D003078	Colchicine	Colchicine results in increased expression of EDNRB mRNA	20624997
D003300	Copper	Copper results in increased expression of EDNRB mRNA	30556269
C513821	CPU0213	CPU0213 inhibits the reaction [Isoproterenol results in increased expression of EDNRB mRNA]	18594475
D003471	Cuprizone	Cuprizone results in increased expression of EDNRB mRNA	26577399; 27523638;
D003513	Cycloheximide	Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]	20561571
D003513	Cycloheximide	Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]	20561571
D003513	Cycloheximide	Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
D003513	Cycloheximide	Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571
D003513	Cycloheximide	Cycloheximide inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]	20716444
D003520	Cyclophosphamide	Cyclophosphamide results in increased expression of EDNRB mRNA	20849824
D016572	Cyclosporine	3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Cyclosporine results in increased expression of EDNRB mRNA]	25772258
D016572	Cyclosporine	3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Cyclosporine results in increased expression of EDNRB protein]	25772258
D016572	Cyclosporine	Celecoxib inhibits the reaction [Cyclosporine results in decreased expression of EDNRB protein]	24462674
D016572	Cyclosporine	Celecoxib inhibits the reaction [Cyclosporine results in increased expression of EDNRB protein]	25656942
D016572	Cyclosporine	Cyclosporine results in decreased expression of EDNRB protein	24462674; 25656942;
D016572	Cyclosporine	Cyclosporine results in increased expression of EDNRB mRNA	25772258
D016572	Cyclosporine	Cyclosporine results in increased expression of EDNRB protein	25772258
D016572	Cyclosporine	Dactinomycin inhibits the reaction [Cyclosporine results in increased expression of EDNRB mRNA]	25772258
D016572	Cyclosporine	SB 203580 inhibits the reaction [Cyclosporine results in increased expression of EDNRB mRNA]	25772258
D016572	Cyclosporine	SB 203580 inhibits the reaction [Cyclosporine results in increased expression of EDNRB protein]	25772258
D016572	Cyclosporine	U 0126 inhibits the reaction [Cyclosporine results in increased expression of EDNRB mRNA]	25772258
D016572	Cyclosporine	U 0126 inhibits the reaction [Cyclosporine results in increased expression of EDNRB protein]	25772258
C077420	Cys(11)-Cys(15)-endothelin-1 (11-21)	Cys(11)-Cys(15)-endothelin-1 (11-21) results in decreased activity of EDNRB protein	15685554
D003609	Dactinomycin	Dactinomycin inhibits the reaction [Cyclosporine results in increased expression of EDNRB mRNA]	25772258
D003609	Dactinomycin	Dactinomycin inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]	20561571
D003609	Dactinomycin	Dactinomycin inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]	20561571
D003609	Dactinomycin	Dactinomycin inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
D003609	Dactinomycin	Dactinomycin inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571
D003609	Dactinomycin	Dactinomycin inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]	20716444
D003609	Dactinomycin	Dactinomycin inhibits the reaction [TNF protein results in increased expression of EDNRB mRNA]	22207076
D003630	Daunorubicin	Daunorubicin results in increased expression of EDNRB protein	20888384
D003630	Daunorubicin	Telmisartan promotes the reaction [Daunorubicin results in increased expression of EDNRB protein]	20888384
D003907	Dexamethasone	Dexamethasone results in increased expression of EDNRB mRNA	21356098
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDNRB mRNA	28628672
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of EDNRB mRNA	28628672
D003907	Dexamethasone	Dexamethasone promotes the reaction [nitrofen results in increased expression of EDNRB mRNA]	10693666
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of EDNRB mRNA	17361019; 21266533;
D004041	Dietary Fats	Dietary Fats results in decreased expression of EDNRB mRNA	18042831; 25016146;
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in increased expression of EDNRB mRNA	20920545
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of EDNRB mRNA	19638242
D004121	Dimethyl Sulfoxide	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]	20561571
D004121	Dimethyl Sulfoxide	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]	20561571
D004121	Dimethyl Sulfoxide	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter promotes the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]]	20561571
D004121	Dimethyl Sulfoxide	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter promotes the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]]	20561571
D004121	Dimethyl Sulfoxide	Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]	20561571
D004121	Dimethyl Sulfoxide	Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]	20561571
D004121	Dimethyl Sulfoxide	Dactinomycin inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]	20561571
D004121	Dimethyl Sulfoxide	Dactinomycin inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]	20561571
D004121	Dimethyl Sulfoxide	Dimethyl Sulfoxide results in increased expression of EDNRB mRNA	20561571
D004121	Dimethyl Sulfoxide	Dimethyl Sulfoxide results in increased expression of EDNRB protein	20561571
D004121	Dimethyl Sulfoxide	pyrazolanthrone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]	20561571
D004121	Dimethyl Sulfoxide	pyrazolanthrone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]	20561571
D004121	Dimethyl Sulfoxide	wedelolactone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]	20561571
D004121	Dimethyl Sulfoxide	wedelolactone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]	20561571
D015237	Dinoprost	Dinoprost results in increased expression of EDNRB mRNA	20484870
C516138	dorsomorphin	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
D004726	Endosulfan	Endosulfan results in increased expression of EDNRB mRNA	29391264
C098288	enrasentan	enrasentan binds to and results in decreased activity of EDNRB protein	16219361
C118739	entinostat	entinostat results in increased expression of EDNRB mRNA	26272509
C118739	entinostat	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C045651	epigallocatechin gallate	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EDNRB mRNA	22079256
D011464	Epoprostenol	EDNRB protein affects the secretion of Epoprostenol	11067800
D004958	Estradiol	[Estradiol co-treated with Progesterone] results in decreased expression of EDNRB mRNA	20660070
D000431	Ethanol	Ethanol results in increased expression of EDNRB mRNA	31059573
D000431	Ethanol	Ethanol results in increased expression of EDNRB mRNA	30319688
D000431	Ethanol	Ethanol results in decreased expression of EDNRB protein	16651399
D004997	Ethinyl Estradiol	[Ethinyl Estradiol co-treated with Cholic Acids] affects the expression of EDNRB mRNA	27344345
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of EDNRB mRNA	23129252
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased mutagenesis of EDNRB gene	17174358; 9475716;
D005047	Etoposide	Etoposide results in decreased expression of EDNRB mRNA	25270620
D005280	Fenoterol	Fenoterol results in increased expression of EDNRB mRNA	16340002
D017313	Fenretinide	Fenretinide results in increased expression of EDNRB mRNA	28973697
D005472	Fluorouracil	Fluorouracil results in decreased expression of EDNRB mRNA	24737281
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of EDNRB mRNA	20938992
D005620	Freund's Adjuvant	Freund's Adjuvant inhibits the reaction [Urethane results in decreased expression of EDNRB mRNA]	12810352
D000077156	Gefitinib	Gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]	18424623
D005839	Gentamicins	Gentamicins results in increased expression of EDNRB mRNA	20849824
D005839	Gentamicins	Gentamicins results in increased expression of EDNRB protein	15200423
D005839	Gentamicins	[Gentamicins results in increased expression of EDNRB protein] which results in increased abundance of Nitrites	15200423
C010176	halofuginone	halofuginone results in increased expression of EDNRB mRNA	17180598
C545476	incobotulinumtoxinA	incobotulinumtoxinA results in increased expression of EDNRB mRNA	29522793
D007213	Indomethacin	Indomethacin inhibits the reaction [IL1B results in increased activity of EDNRB]	12126971
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDNRB mRNA	28628672
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of EDNRB mRNA	28628672
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EDNRB mRNA	25613284
C074308	IRL 1620	IRL 1620 binds to and results in increased activity of EDNRB protein	16151434
C074308	IRL 1620	IRL 1620 binds to and results in increased activity of EDNRB protein	10961375
D007545	Isoproterenol	CPU0213 inhibits the reaction [Isoproterenol results in increased expression of EDNRB mRNA]	18594475
D007545	Isoproterenol	Isoproterenol results in increased expression of EDNRB mRNA	18594475
D007545	Isoproterenol	Isoproterenol results in increased expression of EDNRB protein	27174236
D007545	Isoproterenol	natakalim inhibits the reaction [Isoproterenol results in increased expression of EDNRB protein]	27174236
C119319	J 104132	J 104132 binds to EDNRB protein	11483691
C063302	KN 62	KN 62 inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C063302	KN 62	KN 62 inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
D019344	Lactic Acid	Lactic Acid results in decreased expression of EDNRB mRNA	30851411
C008261	lead acetate	lead acetate results in increased expression of EDNRB mRNA	22839698
C031895	lead chromate	lead chromate results in increased expression of EDNRB mRNA	23584427
C113044	LU 224332	LU 224332 binds to and results in decreased activity of EDNRB protein	15754391
C113044	LU 224332	LU 224332 binds to and results in decreased activity of EDNRB protein	15838271
C042720	mercuric bromide	mercuric bromide results in increased expression of EDNRB mRNA	26272509
D008694	Methamphetamine	Methamphetamine results in decreased expression of EDNRB mRNA	29802913
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of EDNRB mRNA	20938992
D008727	Methotrexate	Methotrexate affects the expression of EDNRB mRNA	18502557
D008770	Methylnitrosourea	Methylnitrosourea results in increased mutagenesis of EDNRB gene	17174358
D008775	Methylprednisolone	Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDNRB mRNA]	7756592
C008493	methylselenic acid	methylselenic acid results in increased expression of EDNRB mRNA	18548127
D015735	Mifepristone	Mifepristone results in increased expression of EDNRB mRNA	17584828
C063509	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C063509	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in increased activity of NOS1 protein]	15245872
C492919	N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide	N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
C492919	N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide	N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [TNF protein results in increased expression of EDNRB mRNA]	22207076
C492919	N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide	N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [TNF protein results in increased expression of EDNRB protein]	22207076
D037742	Nanotubes, Carbon	Nanotubes, Carbon affects the expression of EDNRB mRNA	23845593
D037742	Nanotubes, Carbon	Nanotubes, Carbon analog results in decreased expression of EDNRB mRNA	25554681; 25620056;
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in decreased expression of EDNRB mRNA	25554681
C556401	natakalim	natakalim inhibits the reaction [Isoproterenol results in increased expression of EDNRB protein]	27174236
C556401	natakalim	natakalim results in decreased expression of EDNRB protein	25215478
C017096	n-butoxyethanol	n-butoxyethanol results in increased expression of EDNRB mRNA	19812364
D009525	Niacin	LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of EDNRB mRNA]	16940432
D009538	Nicotine	Nicotine results in increased activity of EDNRB protein	21316381
C012655	nimesulide	nimesulide inhibits the reaction [IL1B results in increased activity of EDNRB]	12126971
D009569	Nitric Oxide	[EDN1 protein results in increased activity of EDNRB protein] which results in increased abundance of Nitric Oxide	16380457
D009569	Nitric Oxide	EDN1 protein promotes the reaction [EDNRB protein results in increased chemical synthesis of Nitric Oxide]	10976779
D009569	Nitric Oxide	EDNRB protein affects the secretion of Nitric Oxide	11067800
D009569	Nitric Oxide	EDNRB protein results in increased chemical synthesis of Nitric Oxide	10976779
D009573	Nitrites	[Gentamicins results in increased expression of EDNRB protein] which results in increased abundance of Nitrites	15200423
C007350	nitrofen	Dexamethasone promotes the reaction [nitrofen results in increased expression of EDNRB mRNA]	10693666
C007350	nitrofen	nitrofen results in increased expression of EDNRB mRNA	10693666; 19851775;
C007350	nitrofen	nitrofen results in increased expression of EDNRB protein	19851775
D009599	Nitroprusside	Nitroprusside inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]	16023617
D009599	Nitroprusside	Nitroprusside inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]	16023617
D018817	N-Methyl-3,4-methylenedioxyamphetamine	N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of EDNRB mRNA	26251327
C025256	nonylphenol	nonylphenol results in increased expression of EDNRB mRNA	15620428
D009638	Norepinephrine	[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine	16023617
D009638	Norepinephrine	[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine	16023617
C484027	oligofectamine	oligofectamine results in increased expression of EDNRB mRNA	14668052
D010100	Oxygen	Oxygen deficiency results in increased expression of EDNRB mRNA	24236059
D010100	Oxygen	[NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of EDNRB mRNA	30529165
D010100	Oxygen	Oxygen deficiency results in increased expression of EDNRB mRNA	21926265
D010100	Oxygen	Oxygen deficiency results in increased expression of EDNRB protein	21926265
D010100	Oxygen	Oxygen results in increased expression of EDNRB mRNA	25203536
D010100	Oxygen	Rosiglitazone inhibits the reaction [Oxygen deficiency results in increased expression of EDNRB mRNA]	21926265
D010100	Oxygen	Rosiglitazone inhibits the reaction [Oxygen deficiency results in increased expression of EDNRB protein]	21926265
D010100	Oxygen	Oxygen deficiency results in decreased expression of EDNRB protein	28985491
D010100	Oxygen	tanshinone inhibits the reaction [Oxygen deficiency results in decreased expression of EDNRB protein]	28985491
D010126	Ozone	[Ozone co-treated with Vehicle Emissions] results in increased expression of EDNRB mRNA	20980218
D010126	Ozone	Ozone results in increased expression of EDNRB mRNA	16081523; 20980218;
D000073878	Palm Oil	Palm Oil results in decreased expression of EDNRB mRNA	18042831
D000077767	Panobinostat	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
D000077767	Panobinostat	Panobinostat results in increased expression of EDNRB mRNA	26272509
C084656	paricalcitol	[Phosphorus co-treated with paricalcitol] affects the expression of EDNRB mRNA	17715259
D052638	Particulate Matter	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter promotes the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]]	20561571
D052638	Particulate Matter	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter promotes the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]]	20561571
D052638	Particulate Matter	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
D052638	Particulate Matter	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571
D052638	Particulate Matter	Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
D052638	Particulate Matter	Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571
D052638	Particulate Matter	Dactinomycin inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
D052638	Particulate Matter	Dactinomycin inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571
D052638	Particulate Matter	Particulate Matter results in increased expression of EDNRB mRNA	16081523; 20561571; 26496744;
D052638	Particulate Matter	Particulate Matter results in increased expression of EDNRB protein	20561571; 26496744;
D052638	Particulate Matter	pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
D052638	Particulate Matter	pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571; 26496744;
D052638	Particulate Matter	SB 203580 inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
D052638	Particulate Matter	SB 203580 inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571; 26496744;
D052638	Particulate Matter	Staurosporine inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
D052638	Particulate Matter	Staurosporine inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571
D052638	Particulate Matter	U 0126 inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	26496744
D052638	Particulate Matter	wedelolactone inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
D052638	Particulate Matter	wedelolactone inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571
C082887	PD 145065	PD 145065 binds to and results in decreased activity of EDNRB protein	17578707
C106950	PD 156252	PD 156252 binds to and results in decreased activity of EDNRB protein	11751199
C101814	perfluoro-n-undecanoic acid	perfluoro-n-undecanoic acid results in decreased expression of EDNRB mRNA	23602845
D010634	Phenobarbital	Phenobarbital affects the expression of EDNRB mRNA	23091169
D010656	Phenylephrine	Phenylephrine results in increased expression of EDNRB protein	15007106
D010662	Phenylmercuric Acetate	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of EDNRB mRNA	26272509
C008890	phosphoramidon	phosphoramidon results in increased expression of EDNRB protein	15007106
D010758	Phosphorus	[Phosphorus co-treated with paricalcitol] affects the expression of EDNRB mRNA	17715259
D010852	Picrotoxin	Picrotoxin results in decreased expression of EDNRB mRNA	15170462
C121565	pifithrin	pifithrin results in decreased expression of EDNRB mRNA	19098008
D010972	Platelet Activating Factor	EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]	18205269
D010972	Platelet Activating Factor	EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]	18205269
D011189	Potassium Chloride	[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA	18823320
D011189	Potassium Chloride	Atrasentan inhibits the reaction [[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA]	18823320
C027373	potassium chromate(VI)	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EDNRB mRNA	22079256
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of EDNRB mRNA	22079256
D011374	Progesterone	[Estradiol co-treated with Progesterone] results in decreased expression of EDNRB mRNA	20660070
D011374	Progesterone	Progesterone results in increased expression of EDNRB mRNA	21540246
D011374	Progesterone	Progesterone results in increased expression of EDNRB mRNA	19690047
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of EDNRB mRNA	24780913
D011692	Puromycin Aminonucleoside	Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDNRB mRNA]	7756592
D011692	Puromycin Aminonucleoside	Puromycin Aminonucleoside results in increased expression of EDNRB mRNA	7756592
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]	20561571
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]	20561571
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571; 26496744;
C432165	pyrazolanthrone	pyrazolanthrone inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]	20716444
D011794	Quercetin	Quercetin results in increased expression of EDNRB mRNA	21356098
D011794	Quercetin	Quercetin results in increased expression of EDNRB mRNA	15309432
D011794	Quercetin	Quercetin affects the expression of EDNRB mRNA	18178720
D012256	Riboflavin	Riboflavin results in increased expression of EDNRB mRNA	21356098
C116926	rofecoxib	rofecoxib inhibits the reaction [IL1B results in increased activity of EDNRB]	12126971
D000077154	Rosiglitazone	Rosiglitazone results in increased expression of EDNRB mRNA	20516393
D000077154	Rosiglitazone	Rosiglitazone results in increased expression of EDNRB protein	20516393
D000077154	Rosiglitazone	Rosiglitazone inhibits the reaction [Oxygen deficiency results in increased expression of EDNRB mRNA]	21926265
D000077154	Rosiglitazone	Rosiglitazone inhibits the reaction [Oxygen deficiency results in increased expression of EDNRB protein]	21926265
D000077154	Rosiglitazone	Rosiglitazone promotes the reaction [[PPARG protein binds to EDNRB promoter] which results in increased expression of EDNRB mRNA]	20516393; 20516393;
D000077154	Rosiglitazone	Rosiglitazone results in increased expression of EDNRB mRNA	21172411
C057354	sarafotoxins s6	sarafotoxins s6 binds to and results in increased activity of EDNRB protein	15072961
C057354	sarafotoxins s6	sarafotoxins s6 binds to and results in increased activity of EDNRB protein	12056553; 12363203; 12686472; 15334381; 15680467; 15685554; 16335286; 20716444;
C093642	SB 203580	SB 203580 inhibits the reaction [Cyclosporine results in increased expression of EDNRB mRNA]	25772258
C093642	SB 203580	SB 203580 inhibits the reaction [Cyclosporine results in increased expression of EDNRB protein]	25772258
C093642	SB 203580	SB 203580 inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
C093642	SB 203580	SB 203580 inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571; 26496744;
C093642	SB 203580	SB 203580 inhibits the reaction [Smoke results in increased expression of EDNRB mRNA]	18718921
C093642	SB 203580	SB 203580 inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
C406525	SB 239063	SB 239063 inhibits the reaction [Smoke results in increased expression of EDNRB mRNA]	18718921
C406525	SB 239063	SB 239063 inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
D012906	Smoke	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
D012906	Smoke	Cycloheximide inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]	20716444
D012906	Smoke	Dactinomycin inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]	20716444
D012906	Smoke	N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
D012906	Smoke	pyrazolanthrone inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]	20716444
D012906	Smoke	SB 203580 inhibits the reaction [Smoke results in increased expression of EDNRB mRNA]	18718921
D012906	Smoke	SB 203580 inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
D012906	Smoke	SB 239063 inhibits the reaction [Smoke results in increased expression of EDNRB mRNA]	18718921
D012906	Smoke	SB 239063 inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
D012906	Smoke	Smoke analog results in increased expression of EDNRB protein	20716444
D012906	Smoke	Smoke results in increased expression of EDNRB mRNA	18718921
D012906	Smoke	Smoke results in increased expression of EDNRB protein	18718921
D012906	Smoke	U 0126 inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]	20716444
D012906	Smoke	U 0126 inhibits the reaction [Smoke results in increased expression of EDNRB mRNA]	18718921
D012906	Smoke	U 0126 inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
D012906	Smoke	wedelolactone inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
C017947	sodium arsenite	sodium arsenite inhibits the reaction [EDN1 protein results in increased expression of EDNRB]	28470405
C017947	sodium arsenite	sodium arsenite results in increased expression of EDNRB mRNA	20371982
D012965	Sodium Chloride	[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA	18823320
D012965	Sodium Chloride	Atrasentan inhibits the reaction [[19-oxo-11-deoxycorticosterone acetate co-treated with Potassium Chloride co-treated with Sodium Chloride] results in decreased expression of EDNRB mRNA]	18823320
D053260	Soot	Soot affects the expression of EDNRB mRNA	26551751
D019311	Staurosporine	Staurosporine inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
D019311	Staurosporine	Staurosporine inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571
C088196	TAK 044	TAK 044 binds to and results in decreased activity of EDNRB protein	11327643
C557331	TAK-875	TAK-875 results in increased expression of EDNRB mRNA	30243991
C021751	tanshinone	tanshinone inhibits the reaction [Oxygen deficiency results in decreased expression of EDNRB protein]	28985491
D000077333	Telmisartan	Telmisartan promotes the reaction [Daunorubicin results in increased expression of EDNRB protein]	20888384
D013739	Testosterone	Testosterone affects the expression of EDNRB mRNA	12122504; 14616470;
C004648	testosterone enanthate	testosterone enanthate affects the expression of EDNRB mRNA	17440010
D013749	Tetrachlorodibenzodioxin	AHR gene SNP affects the reaction [Tetrachlorodibenzodioxin results in increased expression of EDNRB mRNA]	25445724
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of EDNRB mRNA	22298810
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of EDNRB mRNA	20106945
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of EDNRB mRNA	25445724
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of EDNRB mRNA	19465110
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EDNRB mRNA	25613284
C120582	tezosentan	tezosentan binds to and results in decreased activity of EDNRB protein	16219361
C120582	tezosentan	tezosentan binds to and results in decreased activity of EDNRB protein	16181825; 16327003; 16339822;
D013849	Thimerosal	Thimerosal results in decreased expression of EDNRB mRNA	27188386
C009495	titanium dioxide	titanium dioxide results in decreased expression of EDNRB mRNA	23557971
C009495	titanium dioxide	titanium dioxide results in increased expression of EDNRB mRNA	29264374
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of EDNRB mRNA	22363418
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of EDNRB mRNA	20133372
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of EDNRB mRNA	22952915
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of EDNRB protein	22952915
C082097	tocotrienol, delta	tocotrienol, delta results in increased expression of EDNRB mRNA	21356098
D014118	Toxins, Biological	Toxins, Biological affects the expression of EDNRB mRNA	19682533
D014212	Tretinoin	Tretinoin results in decreased expression of EDNRB mRNA	21934132
C012589	trichostatin A	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
C012589	trichostatin A	trichostatin A results in increased expression of EDNRB mRNA	24935251; 26272509;
D000077288	Troglitazone	Troglitazone results in decreased expression of EDNRB mRNA	28973697
C113580	U 0126	U 0126 inhibits the reaction [Cyclosporine results in increased expression of EDNRB mRNA]	25772258
C113580	U 0126	U 0126 inhibits the reaction [Cyclosporine results in increased expression of EDNRB protein]	25772258
C113580	U 0126	U 0126 inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	26496744
C113580	U 0126	U 0126 inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]	20716444
C113580	U 0126	U 0126 inhibits the reaction [Smoke results in increased expression of EDNRB mRNA]	18718921
C113580	U 0126	U 0126 inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
C419664	udenafil	udenafil results in decreased expression of EDNRB	21366883
D014520	Urethane	Freund's Adjuvant inhibits the reaction [Urethane results in decreased expression of EDNRB mRNA]	12810352
D014520	Urethane	IFNG protein inhibits the reaction [Urethane results in decreased expression of EDNRB mRNA]	12810352
D014520	Urethane	Urethane results in decreased expression of EDNRB mRNA	12810352
D014635	Valproic Acid	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of EDNRB mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of EDNRB mRNA	19101580; 23179753; 24383497; 24935251; 26272509; 27188386; 28001369;
D001335	Vehicle Emissions	Vehicle Emissions affects the methylation of EDNRB gene	25560391
D001335	Vehicle Emissions	[Ozone co-treated with Vehicle Emissions] results in increased expression of EDNRB mRNA	20980218
D000069470	Venlafaxine Hydrochloride	Venlafaxine Hydrochloride results in increased expression of EDNRB mRNA	25423262
D014747	Vinblastine	Vinblastine results in increased expression of EDNRB mRNA	20624997
D014750	Vincristine	Vincristine results in increased expression of EDNRB mRNA	20624997
D014800	Vitallium	Vitallium analog results in increased expression of EDNRB mRNA	23825117
D000077337	Vorinostat	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA	27188386
D000077337	Vorinostat	Vorinostat results in increased expression of EDNRB mRNA	26272509
C051122	wedelolactone	wedelolactone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]	20561571
C051122	wedelolactone	wedelolactone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]	20561571
C051122	wedelolactone	wedelolactone inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]	20561571
C051122	wedelolactone	wedelolactone inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]	20561571
C051122	wedelolactone	wedelolactone inhibits the reaction [Smoke results in increased expression of EDNRB protein]	18718921
C051122	wedelolactone	wedelolactone inhibits the reaction [TNF protein results in increased expression of EDNRB mRNA]	22207076
C051122	wedelolactone	wedelolactone inhibits the reaction [TNF protein results in increased expression of EDNRB protein]	22207076
C415840	ZD 2574	ZD 2574 binds to and results in decreased activity of EDNRB protein	11046091
D015032	Zinc	Zinc results in decreased expression of EDNRB mRNA	17074742
D019287	Zinc Sulfate	Zinc Sulfate results in decreased expression of EDNRB mRNA	17074742

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0015	Albinism
KW-0025	Alternative splicing
KW-1003	Cell membrane
KW-0209	Deafness
KW-0225	Disease mutation
KW-1015	Disulfide bond
KW-0297	G-protein coupled receptor
KW-0325	Glycoprotein
KW-0367	Hirschsprung disease
KW-0449	Lipoprotein
KW-0472	Membrane
KW-0564	Palmitate
KW-0597	Phosphoprotein
KW-0621	Polymorphism
KW-0675	Receptor
KW-1185	Reference proteome
KW-0732	Signal
KW-0807	Transducer
KW-0812	Transmembrane
KW-1133	Transmembrane helix
KW-0897	Waardenburg syndrome

Interpro

InterPro ID	InterPro Term
IPR000499	Endthln_rcpt
IPR001112	ETB_rcpt
IPR000276	GPCR_Rhodpsn
IPR017452	GPCR_Rhodpsn_7TM

PROSITE

PROSITE ID	PROSITE Term
PS00237	G_PROTEIN_RECEP_F1_1
PS50262	G_PROTEIN_RECEP_F1_2

Pfam

Pfam ID	Pfam Term
PF00001	7tm_1

Gene: EDNRB

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction